- DOJ reaches largest-ever federal government settlement over auto loan discrimination
- U.S. Navy to start giving gay couples marriage benefits in Japan
- Sen. Harry Reid goes to hospital as a precaution
- Fla.’s Trey Radel exits rehab, ‘excited’ to resume congressional role
- U.S. nuclear general boozed it up, chased ‘hot women’ in Russia: report
- 45 Calif. students at one school test positive for tuberculosis exposure
- Rob Ford on women: Give them cash ‘and they are happy’
- Ku Klux Klan group holds recruitment meeting in Maryland
- Airport assassination: Mayor, 3 others killed at Manila airport
- Tea party-type lawmakers take mysterious, off-books trip to Mideast
Read takes over a Pfizer facing many difficulties
Question of the Day
NEW YORK (AP) - Pfizer Inc. may be the world’s biggest drugmaker, but new CEO Ian Read is taking charge at a trying time for the company, and he will have to deal with a declining share price, repeated failures of potential new products and expirations of patents on key drugs.
Pfizer said Sunday that Read is replacing Jeffrey Kindler, who was Pfizer’s CEO for four-and-a-half years. Read, 57, has worked at Pfizer for more than 30 years in a variety of positions and countries, making him a potential contrast to Kindler, who was an executive for McDonald’s Corp. and a director of the New York branch of the Federal Reserve before he joined Pfizer.
While Kindler’s exit came as a surprise, analysts said the choice of Read indicates big changes are not immediately in store for the company.
Still, control of Pfizer could be shifting. Read is likely to have less say in Pfizer’s direction than Kindler did because, unlike Kindler, he won’t be the chairman of Pfizer’s board. However Read is getting the newly created role of company president.
Pfizer shares gained 9 cents to $16.81. The stock is down 9.6 percent over the last year.
Jefferies & Co. analyst Jeffrey Holford said Read is “a safe pair of hands,” who is familiar with Pfizer.
“We are confident that the transition will be smooth and likely beneficial to the company as it becomes increasingly diversified, given Mr. Read’s extensive experience with the company’s key operations,” he said in a note to clients.
But are larger changes needed? In late 2011, the patent on Pfizer’s best-selling drug, the cholesterol medication Lipitor, will expire. Lipitor brings Pfizer almost $13 billion in annual sales, and after the patent expires, generic competition will reach the market and sales of its drug will plunge. This year the patents on Pfizer’s antidepressant Effexor XR and Alzheimer’s drug Aricept expired. More will follow, including billion-dollar sellers impotence drug Viagra, in 2012, and pain reliever Celebrex, in 2014. The company has had trouble developing drugs to replace those products.
The company has seen at least half a dozen drugs fail in the last stage of clinical testing in the last year and a half, including its Alzheimer’s disease treatment Dimebon, osteoarthritis treatment tanezumab, and cancer drug figitumumab. Multiple trials that were designed to expand the marketing approval of its cancer drug Sutent also failed. Failure of the trials was due to ineffectiveness or safety problems.
Professor Erik Gordon of the University of Michigan’s Ross School of Business said Read would be “safe” and “no-nonsense,” but that those traits alone were not enough to turn Pfizer’s fortunes around. In an e-mail, Gordon said Pfizer needs to figure out how to avoid costly failures in late-stage clinical testing.
“What Pfizer needs is leadership to rebuild a broken research and development organization,” he said.
The company’s pipeline difficulties continued Monday when the company said its drug candidate bosutinib was not significantly better than another cancer drug at treating chronic myeloid leukemia. It said bosutinib did not outperform Novartis AG’s drug Gleevec in a late-stage trial.
The company has reported successes with studies of its lung cancer drug crizotinib and heart drug Inspra. Some studies of its blood thinner apixaban have been successful, but last month Pfizer stopped a trial because the drug was linked to an increased risk of bleeding. Pfizer is developing apixaban with Bristol-Myers Squibb Co.
Kindler sought to offset the pipeline expirations in part by wheeling and dealing. A little more than a year ago, Pfizer bought rival Wyeth for $68 billion, and it is in the process of buying King Pharmaceuticals Inc. for $3.6 billion. But analyst Les Funtledeyer of Miller Tabak & Co. said the Wyeth deal has not lived up to its billing so far.
“I don’t think the Wyeth acquisition met the expectations that a lot of people had for how much it would improve Pfizer’s standing, in contrast to Merck-Schering-Plough,” he said in a telephone interview, contrasting it with Merck’s $46 billion purchase, which closed about a month after Pfizer bought Wyeth.
By John McAfee
- Breaking Fad: Alligators becoming the new pit bulls for drug dealers, cops say
- D.C. to tout Obamacare among youth waiting for Air Jordans
- Huge backlash mounts over suspension of 'Duck Dynasty' star Phil Robertson
- TARGET credit card theft swells to 40 million victims
- Special ops vets slam military benefit cuts
- Obama: 2014 will be 'breakthrough year' for U.S.
- Dems use new filibuster rules to approve DHS nominee Alejandro Mayorkas under investigation
- Obamacare 'pajamas boy' gets roundly mocked
- Citing 'unfair system,' Obama commutes sentences for 8 crack offenders
- Homeland Security helps smuggle illegal immigrant children into the U.S.
Independent voices from the The Washington Times Communities
Our Choice: Individual responsibility and self-government or the abandonment of the American Revolution
Al Maurer provides a common sense, conservatarian, Constitutional conservative perspective from the battleground state of Colorado
Top 10 handguns in the U.S.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow